Relevant bibliographies by topics / Thrombosis

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Thrombosis'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 September 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Thrombosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Thrombosis"

1

Sands, Jeffrey J., and Carol L. Miranda. "State-of-the-Art Review : Treatment of Hemodialysis Access Failure: A Role for Thrombolysis." Clinical and Applied Thrombosis/Hemostasis 2, no. 3 (July 1996): 164–68. http://dx.doi.org/10.1177/107602969600200304.

Full text
Abstract:
Thrombosis of hemodialysis accesses remains a major source of morbidity, hospitalization, and expense for patients with end-stage renal disease. Treatment of hemodialysis accesses includes strategies to prevent ac cess failure and methods for treating acute thromboses. Such techniques as Doppler ultrasonography, venous pressure monitoring during dialysis, measurement of ra tios of venous to systemic pressures, and measurement of recirculation have been used to predict accesses at risk of thrombosis. Elective interventions, including surgical re visions and angioplasties, have been shown to lessen the thrombosis rate in both polytetrafluoroethylene (PTFE) grafts and arterio-venous fistulas. Elective revision has also improved long-term patency of both grafts and fistu las when compared with repairing the accesses only after thrombosis. Despite these attempts, acute thrombosis of hemodialysis accesses remains a common complication for patients with end-stage renal disease. Historically, surgical thrombectomy has been the gold standard for treatment of acute hemodialysis access failure. Over the past 10 years, thrombolytic therapy has gained an in creasing role in the treatment of acutely thrombosed PTFE grafts. Thrombolysis has had at least comparable results to surgical thrombectomy in the best centers, with similar complication rates. Thrombolytic therapy is also significantly less expensive than surgical thrombectomy. In summary, we believe that hemodialysis access treat ment should encompass a comprehensive program, in cluding access surveillance to select accesses at risk of failure. Elective intervention should be performed in an attempt to prevent thrombosis and increase long-term ac cess patency. When thrombosis does occur, pharmaco mechanical thrombolysis is the preferable first interven tion for acutely occluded PTFE hemodialysis accesses.
APA, Harvard, Vancouver, ISO, and other styles
2

Kitchens, Craig S. "Thrombotic Storm: When Thrombosis Begets Thrombosis." American Journal of Medicine 104, no. 4 (April 1998): 381–85. http://dx.doi.org/10.1016/s0002-9343(98)00061-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mulcaire-Jones, John P., David K. Bailly, Deborah U. Frank, Anupam R. Verma, Bradley J. Barney, and Heather M. Siefkes. "Spontaneous aortic thrombosis in neonates: a case report and review of literature." Cardiology in the Young 30, no. 1 (January 2020): 95–99. http://dx.doi.org/10.1017/s1047951119003093.

Full text
Abstract:
AbstractNeonatal aortic thrombosis is a rare occurrence but can be life-threatening. Most aortic thrombosis in neonates is related to umbilical artery catheters. A case of a neonate with a spontaneous aortic thrombosis is described here along with a comprehensive review of the literature for cases of neonatal aortic thrombosis not related to any intravascular device or procedure. The aetiologies of these spontaneous thromboses and the relevance of hypercoagulable disorders are discussed. The cases were analysed for odds of death by treatment method adjusted for era. The reference treatment method was thrombolysis and anticoagulation. No other treatment modality had significantly lower odds than the reference. Surgery alone had higher odds for death than the reference, but this may be confounded by severity of case. The management recommendations for clinicians encountering neonates with spontaneous neonatal aortic thrombosis are discussed.
APA, Harvard, Vancouver, ISO, and other styles
4

Spaet, Theodore H. "Thrombosis and Thrombolysis." JAMA: The Journal of the American Medical Association 257, no. 19 (May 15, 1987): 2653. http://dx.doi.org/10.1001/jama.1987.03390190131040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hongsakul, Keerati, Sorracha Rookkapan, Jitpreedee Sungsiri, Ussanee Boonsrirat, and Boonprasit Kritpracha. "Pharmacomechanical Thrombolysis versus Surgical Thrombectomy for the Treatment of Thrombosed Haemodialysis Grafts." Annals of the Academy of Medicine, Singapore 44, no. 2 (February 15, 2015): 66–70. http://dx.doi.org/10.47102/annals-acadmedsg.v44n2p66.

Full text
Abstract:
Introduction: The key to treatment of a thrombosed dialysis graft is restoration and maintenance of function as long as possible. The objective of this study was to compare the outcomes of pharmacomechanical thrombolysis and surgical thrombectomy in the treatment of thrombosed haemodialysis grafts. Materials and Methods: During a 3-year period, 108 patients with 114 thrombosed dialysis grafts were referred to our institute for treatment. Fifty thrombosed dialysis grafts underwent pulse-spray catheter thrombolysis using recombinant tissue plasminogen activator (rt-PA) with angioplasty, and 64 thrombosed dialysis grafts underwent surgical thrombectomy. The procedural success rates, complications and average patency times and patency rates were compared between the 2 procedures. P values less than 0.05 were considered to be statistically significant. Results: There were no statistically significant differences between the pharmacomechanical thrombolysis group and the thrombectomy group in the procedural success rates (94% and 93.8%, P = 0.15) or average patency times (6.24 months and 6.30 months, P = 0.17). The primary and secondary patency rates at 12 months were 28.0% ± 8.4% and 54.3% ± 7.8% for the thrombolysis with angioplasty group, and 30.0% ± 6.3% and 57.0% ± 4.8% for the thrombectomy group, respectively (P = 0.65 and P = 0.49, respectively). There were no procedural-related major complications. Conclusion: Our study found no differences in outcomes between patients treated with pharmacomechanical thrombolysis and surgical thrombectomy for thrombosed haemodialysis grafts. Pharmacomechanical thrombolysis can be considered as an alternative treatment for dialysis graft thrombosis. Key words: Angioplasty, Arteriovenous graft, Thrombosis
APA, Harvard, Vancouver, ISO, and other styles
6

Fraschini, G., J. Jadeja, M. Lawson, F. A. Holmes, H. C. Carrasco, and S. Wallace. "Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients." Journal of Clinical Oncology 5, no. 4 (April 1987): 672–78. http://dx.doi.org/10.1200/jco.1987.5.4.672.

Full text
Abstract:
We assessed the efficacy of local fibrinolytic therapy in 35 axillary-subclavian vein thromboses (SVT) that occurred in cancer patients with percutaneous central venous catheters (CVC). These catheters were indwelling for a median of 1 month (range, one day to 10 months) before thrombosis developed. Urokinase was administered at a dose of 500 to 2,000 U/kg/h. Complete lysis occurred in 25 of 30 thrombi that were directly infused, after a median of four days. Complete lysis occurred in one of 12 thrombi that could not be directly infused with urokinase and in two of six with associated phlebitis. Eighty-one percent of the thrombi that were symptomatic for less than 1 week before treatment resolved, compared with 56% present for longer than 1 week. Sixteen patients who had complete (12) or partial (four) thrombolysis did not have their CVCs removed. All four patients with partial thrombolysis had recurrent thrombosis at a median of eight days (range, one to 90). Only two patients who had complete thrombolysis had recurrent thrombosis, at 8 and 16 months. Only minor hemorrhagic toxicity was seen.
APA, Harvard, Vancouver, ISO, and other styles
7

Cote, Julie, Olivier Dumas, Christine Demers, and Julie Lemieux. "Prevalence, risk factors, treatment and outcomes of catheter-related thrombosis in patients with malignancies." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e17517-e17517. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e17517.

Full text
Abstract:
e17517 Background: Tunnelled catheters (Leonard, BARD) and peripherally inserted central catheters (Piccline, BARD) are used for intravenous therapies in patients with malignancies. Thrombosis is a well known complication, but risk factors are not clearly established. The objective the incidence, risk factors, therapeutic approaches and complications of catheter-related thrombosis among patients with malignancies. Methods: Medical charts of patients with malignancies and Leonard or Piccline inserted, from August 2002 to December 2006 at Hôpital de l’Enfant-Jésus (Québec City, Canada), were retrospectively reviewed. Results: A total of 618 catheters were inserted in 361 patients. Eighty-six percent of the catheters were placed in patients with hematologic malignancies and most were Piccline (70%). Sixty-one thromboses were identified (incidence of 10%). Fourteen percent of the patients had more than one episode of catheter-related thrombosis. The majority of thromboses was related to a Piccline (93%) and occurred at a mean time of 34 days after the insertion. At the time of thrombosis, the mean platelet count was 169 x 109/L. Previous history of a catheter-related thrombosis (OR = 4.30 (1.48-12.50); p = 0.0075) as well as lymphoma (OR = 3.29 (1.22-8.87); p = 0.0185) were associated with superficial thromboses. The Piccline was associated with both types of thromboses (OR = 5.78 (1.69-19.74); p = 0.0051), especially with superficial thromboses. Most of the catheters (88%) were removed once a thrombosis was identified. The management of anticoagulation varied considerably. No complication associated with thromboses was reported. Conclusions: The incidence of central venous catheter-related thrombosis was 10%. The thrombosis occurred on average 34 days after the insertion. The Piccline was associated with all types of thromboses, especially the superficial ones. A previous history of catheter-related thrombosis and lymphoma were risk factors for superficial thromboses. Further studies are necessary to better define characteristics and optimal management of central catheter-related thrombosis.
APA, Harvard, Vancouver, ISO, and other styles
8

Mirza, Aram Jamal, and Abdulsalam Yaseen Taha. "Catheter directed thrombolysis for acute deep vein and arterial thrombosis in COVID-19: report of two cases from Sulaymaniyah, Kurdistan-Iraq." Journal of the Faculty of Medicine Baghdad 63, no. 2 (July 13, 2021): 74–79. http://dx.doi.org/10.32007/jfacmedbagdad.6321822.

Full text
Abstract:
Abstract As one year elapsed since COVID-19 outbreak, venous and arterial thromboses are increasingly reported in different vascular territories. Once accessed by the virus, the endothelial cells, abundant in angiotensin converting enzyme-2 (ACE-2) protein, will be activated by the inflammatory process leading to coagulopathy and vascular lesions. Herein, we describe a case of extensive thrombosis of the infra-renal inferior vena cava and iliac femoral vein in a man of 62 and a case of acute superficial femoral artery thrombosis in a lady of 55. Both were COVID-19 confirmed cases with severe pneumonia, high D-Dimer levels and risk factors for severe disease or death. Despite presentation 1-2 weeks after the onset of thromboses, they were successfully managed by catheter directed thrombolysis (CDT) using tissue plasminogen activator (tPA). Owing to the increased morbidity and mortality of vascular thrombosis, there is a need to identify COVID-19 patients who need prophylaxis and prescribe them the right prophylactic drug (s). The excellent outcome of CDT in these two patients, from Sulaymaniyah/Iraq, supports the use of this treatment modality as a valid, safe and effective option for acute arterial and venous thromboses.
APA, Harvard, Vancouver, ISO, and other styles
9

Koraen-Smith, Linn, Matteus Krasun, Matteo Bottai, Ulf Hedin, Carl M. Wahlgren, and Peter Gillgren. "Haemodialysis access thrombosis: Outcomes after surgical thrombectomy versus catheter-directed thrombolytic infusion." Journal of Vascular Access 19, no. 6 (April 3, 2018): 535–41. http://dx.doi.org/10.1177/1129729818761277.

Full text
Abstract:
Introduction: Thrombosis is one of the most common complications of dialysis vascular access and is a significant source of morbidity and healthcare-associated costs. In this retrospective study, outcomes for surgical thrombectomy and thrombolysis after access thrombosis in patients with arteriovenous fistulas or prosthetic grafts (arteriovenous grafts) were analysed. Methods: All patients with a primary episode of dialysis access thrombosis between 2005 and 2013 were included which yielded 131 patients with 149 episodes of access thrombosis (108 arteriovenous grafts; 41 arteriovenous fistulas). In all, 18 patients had two separate accesses during the study. Patient demographics, access anatomy, surgical and radiological procedural data were recorded. Kaplan–Meier estimates and Poisson regression were used for statistical analysis of access patency. Results: In total, 107 underwent surgical thrombectomy and 42 were treated with catheter-directed thrombolytic infusion. Technical success was 60% for surgical thrombectomy and 73% for thrombolysis (p = 0.18). There were no major complications and no deaths within 30 days of the procedure. More patients had adjunctive procedures in the thrombolysis group (65/107 vs 37/42; p = 0.002). There was an increasing risk of rethrombosis or a further access-related event for both arteriovenous fistulas and arteriovenous grafts after open thrombectomy compared with catheter-directed thrombolytic infusion, and arteriovenous fistulas exhibited a lower risk than arteriovenous grafts with an average increase in risk of 23.9% (95% confidence interval: 3.1–49) between each treatment group. Conclusion: Thrombolysis for thrombosis of native and prosthetic dialysis accesses appears to yield better assisted primary patency compared to surgical thrombectomy. Our results suggest that thrombolysis may be considered the first-choice method for treating the thrombosed dialysis access.
APA, Harvard, Vancouver, ISO, and other styles
10

Kröger, K., C. Schelo, C. Gocke, and G. Rudofsky. "Colour Doppler Sonographic Diagnosis of Upper Limb Venous Thromboses." Clinical Science 94, no. 6 (June 1, 1998): 657–61. http://dx.doi.org/10.1042/cs0940657.

Full text
Abstract:
1. Upper limb venous thromboses are considered to be a rare event, but in large hospitals with a lot of patients who receive aggressive intravenous therapy the number of thromboses seem to increase. 2. We have analysed all the cases of upper limb venous thrombosis which occurred at the Essen University Hospital between the years of 1992–1996. All patients were examined using colour Doppler sonography. 3. Out of 827 patients that were examined, a thrombosis was diagnosed in 334 cases. The subclavian vein was involved in 69% of all thromboses. Isolated jugular vein thrombosis was found in 17% of the thromboses, combined thromboses of the jugular and subclavian vein in 19%. In 182 cases the patients were treated for primarily a malignant illness. In 96 cases we found an association with venous port-systems or central venous catheters. 4. More than 40000 patients a year were treated at the university hospital. Considering this huge number of patients the thrombosis of the upper limb is still rare. The use of colour Doppler sonography allows an early and safe diagnosis of the thrombosis without straining the patient.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Thrombosis"

1

Echenique, Javier Jacobo. "Thrombotic fingerprints for the enhanced prediction of thrombosis." Thesis, Massachusetts Institute of Technology, 2007. http://hdl.handle.net/1721.1/39880.

Full text
Abstract:
Thesis (S.M.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering, 2007.
Includes bibliographical references (leaves 111-114).
Controlled thrombosis initiates and regulates tissue repair and remodeling in the vessel wall. Processes from heart attack to stroke, and deep vein thrombosis to pulmonary embolism, are all derived from unrestricted clotting. The frustrating aspects of these diseases lie not only in the difficulty of their timely diagnosis, but in the selection of appropriate therapy, titration of intervention, and identification of patients at risk. Assays like the INR, PTT, and ACT can follow the course of specific pathways that govern activation of specific coagulation factors or platelet function, but they do not provide the insight into mechanism, risk and potential therapeutic benefit. We posit that elucidation of the complex dynamics of clot generation requires an integrated assessment that takes into account all of the factors driving thrombosis simultaneously. Virchow's Triad, has for years been identified as the three critical parameters of clot formation. We propose to examine an individual's clot propensity and response to therapy on minute blood samples, in virtual real time, across a range of flow rates, blood state, and wall conditions with the use of our newly developed in vitro high-throughput testing device.
(cont.) In this manner we will generate a unique thrombotic fingerprint that defines an individual's risk of clotting at a specific point in time over a range of stresses. This fingerprint can aid in tailoring therapeutic clinical treatments, determining the duration and dose of therapy, and assist in clinical trial management and establishment of clinical norms.
by Javier Jacobo Echenique.
S.M.
APA, Harvard, Vancouver, ISO, and other styles
2

Mendez, Rojano Rodrigo. "Thrombosis modeling in blood coated medical devices." Thesis, Montpellier, 2018. http://www.theses.fr/2018MONTS088/document.

Full text
Abstract:
La thrombose est la formation d’un caillot sanguin (thrombus) dans le système cardiovasculaire. Il s’agit d’un des principaux problèmes des dispositifs biomédicaux en contact avec du sang. Toutefois, les biomatériaux utilisés jusqu’à présent dans ces dispositifs déclenchent la coagulation à travers le système de contact. Ce système n’a pas été pris en compte dans les modèles de thrombose dédiés aux dispositifs, alors que son importance pour la thrombose a été récemment remarquée. L’objectif de cette thèse est d’introduire les réactions de coagulation initiées par le système de contact dans la modélisation de la thrombose liées aux dispositifs. Un nouveau modèle réduit pour la génération de thrombine est proposé en incluant l’activation par contact. Le modèle arrive à calculer la formation de thrombine dans du plasma physiologique et du plasma déficient en prothrombine. Une fois réalisée, l’approche réduite est incluse dans un modèle de croissance du thrombus basé sur l’activité des plaquettes. Cette nouvelle stratégie est utilisée pour calculer la formation du thrombus dans une configuration académique
Thrombosis, which is the formation of a blood clot (thrombus) in the vascular system, is one of the major issues of blood-coated medical devices. To reduce thrombosis risk in this type of devices, computational fluid dynamics has been used. Up to date, bio-material surfaces used in blood coated devices initiate blood coagulation through the contact activation system. This system has not been considered in models dedicated to devices, even though its importance in thrombosis has been recently highlighted. The objective of this thesis is to introduce device-triggered coagulation reactions in the modeling of device-related thrombosis.A novel reduced kinetic model including the contact activation system is proposed. The model correctly captures thrombin formation in physiological and prothrombin deficient platelet-poor-plasma. The reduced set of reactions is then included in a platelet-based model for thrombus formation considering platelet activation by thrombin. This approach is used to study thrombus formation in an academic configuration
APA, Harvard, Vancouver, ISO, and other styles
3

Bark, David Lawrence Jr. "The hemodynamics during thrombosis and impact on thrombosis." Diss., Georgia Institute of Technology, 2010. http://hdl.handle.net/1853/37258.

Full text
Abstract:
Atherothrombosis can induce acute myocardial infarction and stroke by progressive stenosis of a blood vessel lumen to full occlusion. The goal of this research is to determine what shear rates are pertinent to an occluding blood vessel, the rate of thrombus growth relative to wall shear rates, and to develop a predictive model for estimating length of time to thrombus occlusion for a given atherosclerotic lesion. Computational studies of severely stenotic idealized vessels were performed to investigate the wall shear rates that may exist. The study shows that maximum shear rates in severe short stenoses were found to exceed 250,000 1/s (9,500 dynes/cm2). We utilize an in vitro experiment consisting of blood flow through a collagen coated stenosis to study the rate of thrombus growth. Growth is monitored through light microscopy and a camera. Computational fluid dynamics are used to determine shear rates along the thrombus surface as it grows. We found a strong positive correlation between thrombus growth rates and shear rates up to 6,000 1/s after a log-log transformation (r=0.85, p<0.0001). Growth rates at pathologic shear rates were typically 2-4 times greater than for physiologic shear rates below 400 s-1. To determine whether transport or kinetic binding limits the rate of thrombus growth, a computational model of platelet transport was developed. The model allows for thrombus growth by occluding computational cells. We show that thrombus is transport rate-limited for shear rates below 6,000 1/s, while it is more likely to be kinetic rate-limited for higher shear rates. Predictions of occlusion times based on the model demonstrate that increases in stenosis severity results in decreased time to occlusion.
APA, Harvard, Vancouver, ISO, and other styles
4

Maclean, Jessica Amy Ann. "Novel approaches to enhance the thrombolytic potential of tissue plasminogen activator (tPA) therapy in stroke." Thesis, University of Sydney, 2020. https://hdl.handle.net/2123/23147.

Full text
Abstract:
Thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) remains the primary pharmacological therapy for acute ischaemic stroke. Despite some significant clinical benefit at three months, rtPA-mediated recanalisation rates remain suboptimal in over 50% of patients receiving this therapy, and cerebral reperfusion is not always achieved with arterial reopening. The aim of these doctoral studies was to investigate novel adjunctive antithrombotic approaches to enhance rtPA-mediated large artery recanalisation and improve cerebral perfusion in a mouse model of stroke. Initial studies focused on the development of the in situ carotid artery thrombo(ly)sis (iCAT) model, the first mouse model of electrolytic-induced carotid artery thrombosis and graded unihemispheric hypoperfusion leading to cerebral infarction. This model allows for the simultaneous real-time assessment of recanalisation, cerebral perfusion and end-organ damage. Extensive characterisation of the iCAT model validated its suitability for the assessment of thrombolytic and adjunctive antithrombotic therapy. Combining rtPA with the anticoagulant therapy (Argatroban) enhanced recanalisation (41.9% vs 22.2% rtPA alone) and significantly improved cerebral perfusion (laser speckle contrast imaging), leading to a moderate reduction in infarct volumes (TTC) at 24 hours. Collectively, these studies present a novel mouse model for the real-time assessment of recanalisation, reperfusion and end-organ damage.
APA, Harvard, Vancouver, ISO, and other styles
5

Landskroner, Kyle Alan. "Thrombosis and Thrombolysis: Emphasis on Hemophilia and Effect of Clot Dissolution with Plasmin." NCSU, 2005. http://www.lib.ncsu.edu/theses/available/etd-08142005-145317/.

Full text
Abstract:
The purpose of this research was to understand the mechanisms in which blood clots form and are degraded. The research studies examined the role of an endogenous protease, plasmin, which is found in all vertebrates, and the optimal doses of plasmin required to dissolve blood clots. When we investigated clot lysis with plasmin we examined blood clots from several species to which varying concentrations of plasmin were added, as well as varying methods of plasmin administration. The results of these studies not only highlighted important dose-response relationships of plasmin, but also demonstrated differences in the effect of human plasmin to dissolve blood clots compared to blood clot from the species tested. Porcine clots, in particular, were more resistant to lysis compared with human clots, while ovine clots had similar lysis compared with human clots. In addition, this research demonstrated that plasmin?s effectiveness to lyse thrombi increases with an increase in clot surface area, e.g, by fragmentation, or when plasmin is administered as an intrathrombic administration. In separate studies, to investigate clot formation, we uesd mice that lack the FVIII protein. For these experiments we investigated the formation of blood clot formation using rotational thromboelastography (ROTEG) that measures the formation of fibrin in whole blood. This method was shown to be extremely sensitive to low levels of factor VIII protein and may have applications to classify particular phenotypes of hemophilia patients, or as a research tool to evaluate novel FVIII molecules.
APA, Harvard, Vancouver, ISO, and other styles
6

Clouston, Hamish. "Thrombosis in colorectal cancer." Thesis, University of Manchester, 2016. https://www.research.manchester.ac.uk/portal/en/theses/thrombosis-in-colorectal-cancer(43d5ef8e-6c59-4fc6-b02c-695898e634d5).html.

Full text
Abstract:
Thrombosis and colorectal cancer have a bi-directional relationship. The presence of a colorectal malignancy results in an increased risk of developing a thrombosis and the presence of a thrombosis results in a worse cancer prognosis. The physiology causing this is at present unclear but it is proposed that proteins from the tissue factor (TF) pathway may be the instigator of this bi-directional relationship. The in-vitro studies have shown that in colorectal cancer TF impairs that action of colorectal cancer stem cells as demonstrated by reduced cancer sphere formation and also lower expression of the stem cell marker ALDH. The ability for a colorectal cell to avoid anoikis is impaired by a reduced TF level. Proliferation is affected by the level of expression of TF with a significant increase in proliferation with additional expression of TF. The increase in proliferation is further increased by the presence of TF’s ligand factor VIIa. Paradoxically reduced expression of TF also increases colorectal cancer expression. The ERK1/2 pathway offers a possible method by which TF and factor VIIa may exert their proliferative effects. In the prospective clinical cohort study (CHAMPion) abnormal expression of TF pathway proteins (TF, PAR1, PAR2 and thrombin) by both malignant epithelial and cancer associated stromal cells has been demonstrated. The stromal expression was independent of the epithelial expression and was only in stroma in close contact (0.1mm) with epithelial cells suggesting that the TF pathway proteins may have a role in stromal/epithelial communication. There was no link between the expression of TF pathway proteins and clinicopathological markers of a poor prognosis. The plasma expression of markers of TF pathway activation did not demonstrate any role as a biomarker for colorectal cancer or prognosis. The CHAMPion study has demonstrated that 7% of patients undergoing surgery for colorectal cancer have asymptomatic pre-operative DVTs present. A further 6% who were DVT free pre-operatively developed a DVT in the peri-operative period despite receiving venous thromboprophylaxis in line with current national guidelines. Pre-operative d-dimer may have the potential to identify those patients at risk of a post-operative VTE.This thesis establishes the role that TF has in promoting proliferation and anoikis resistance. It also confirms the abnormal expression of TF pathway proteins by colorectal cancer epithelial cells and for the first time demonstrates abnormal expression by the cancer associated stroma. The interaction between the stroma and epithelial cells, combined with the cellular effects of TF suggests that targeting this interaction may have a therapeutic role. The incidence of DVTs pre-operatively suggests that screening patients for the asymptomatic presence of a DVT may have an impact on their clinical outcome. The development of DVTs despite prophylaxis suggests that the level of anticoagulation is insufficient and current guidelines need to be revisited.
APA, Harvard, Vancouver, ISO, and other styles
7

Bruce, David. "Antithrombin : structural variants and thrombosis." Thesis, Open University, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.386084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gray, E. "Lipoproteins, blood coagulation and thrombosis." Thesis, Open University, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.372834.

Full text
Abstract:
The main aim of this study was to investigate the involvement of plasma lipoproteins in the blood coagulation system and the implications of this relationship in the pathogenesis of thrombosis. This study has shown that lipid peroxide-induced thrombin generation is caused by a two-fold mechanism: direct interaction of lipid peroxides with lipoprotein phospholipids and inhibition of anti-thrombin III via its heparin-binding site. Experiments using purified lipoproteins have shown that triglyceride-rich lipoproteins, i.e. chylomicra and very low density lipoproteins, are sources of procoagulant activity, whereas low density and high density lipoproteins have little effect. Further work with phospholipids extracted from chylomicra has demonstrated that lipid peroxides interact with the phospholipid component of the lipoprotein molecule and, possibly through an increase in overall negative charge, provide a suitable surface for the binding of clotting factors. Subcutaneous injection of potent lipase releasers, which are weak in vitro anticoagulants, reduce the ex vivo thrombin-generating activity of post-infusion plasma. This reduction in procoagulant activity is caused by the phospholipase action of the hepatic tri-glyceride lipase (HTGL) released. Human HTGL also enhances plasma anti-Xa activity, due to direct inhibition of Xa clotting activity, but the amidolytic activity of Xa is unaffected, thus implying that the serine site of Xa is not preferentially targeted. The phospholipid binding site of Xa appears to be involved, but this anti-Xa effect is not due to the phospholipase action of HTGL. The antithrombotic effects of heparin and heparin analogues may thus be partly due to the release of HTGL, which can reduce pro-coagulant activity via inhibition of lipid peroxide-induced thrombin generation and enhancement of plasma anti-Xa activity.
APA, Harvard, Vancouver, ISO, and other styles
9

Saraf, Smriti. "Assessment of thrombotic and thrombolytic status in patients with coronary artery disease and its relation to clinical outcomes." Thesis, University of Hertfordshire, 2014. http://hdl.handle.net/2299/15000.

Full text
Abstract:
Background: Platelets provide the initial haemostatic plug at sites of vascular injury. They also participate in pathological thrombosis that leads to myocardial infarction, stroke and peripheral vascular disease. The outcome of an acute myocardial infarction depends not only on the formation and stability of an occlusive thrombus, but also on the efficacy of the endogenous thrombolytic process, which allows reperfusion of the infarct related artery and prevents recurrent ischaemic episodes. Various platelet function tests are available to measure the thrombogenic potential of an individual, but the sensitivity of these tests remain questionable as most of these tests use citrated blood and measure response to a particular agonist. Endogenous thrombolysis has been a neglected entity, and its beneficial effects on cardiovascular outcomes has not been studied in depth in the past, possibly as until recently there has been no available technique to measure spontaneous thrombolytic activity in native blood. The Global Thrombosis Test (GTT) is a new point of care tests that allows us to measure time to thrombus formation (Occlusion time: OT) using native blood, avoiding the use of agonists and making the test results more physiological. The GTT also measures the time to lyse this formed thrombi without use of any lytic agents (Lysis time: LT), allowing us to measure the patient’s endogenous thrombolytic potential. Aim: Our aim in this study was to detect patients who are at risk of future thrombotic events despite dual antiplatelet therapy, either due to prothrombotic tendency or due to impaired endogenous thrombolysis, and to determine if these two parameters were correlated. Methods: GTT was used to assess the thrombotic and thrombolytic activity in healthy volunteers, and in different patient populations. 100 healthy volunteers were tested using the GTT, and a normal range was established. 300 patients admitted to hospital with a diagnosis of acute coronary syndrome (ACS) were included in the study, and tested using the GTT after they had been stabilized on dual antiplatelet therapy (Aspirin and Clopidogrel). All these patients were followed up for a year, to determine if their baseline GTT results were a predictor of recurrent cardiac events. The primary endpoint of the study was major adverse cardiovascular events (MACE), which was a composite of cardiovascular death, nonfatal myocardial infarction, or stroke at 12 months. Results: All results were analysed using statistical package SPSS version 16.0 (SPSS Inc., Chicago, Illinois). The 100 healthy volunteers were all non-smokers, and were not taking any medications. There were 55 males and 45 females, and mean age was 38±11 years (range 22-76, IQR 11). OT was normally distributed with mean OT 377.80s, and using mean ± 2SD, we derived a normal range of 185-569s (200-550s). LT demonstrated a skewed distribution with values ranging between 457 – 2934s. Using log transformation, a normal range of 592 – 1923 (600- 2000s) was established for LT. OT and LT were both prolonged in ACS patients compared to normal volunteers (p< 0.001). No association was observed between OT and risk of major adverse cardiovascular events. LT was noted to be a significant and independent predictor of MACE in a multivariate model adjusted for cardiovascular risk factors. LT ≥ 3000 s was the optimal cutoff value for predicting 6 month MACE [hazard ratio (HR): 2.48, 95% CI: 1.2-4.8, P= 0.008] and cardiovascular death [HR: 4.04, 95% CI : 1.3-12.0, P= 0.012 ] and 12 month MACE [HR:1.9, 95% CI: 1.04- 3.5,P= 0.03] and cardiovascular death [HR: 3.9,95% CI: 1.34-11.9, P= 0.013 ]. LT ≥ 3000 s was observed in 23% of ACS patients. Conclusions: Our study suggests that endogenous thrombolytic activity based on lysis of platelet rich thrombi can be assessed by the point of care GTT assay, which can help in identification of ACS patients at high risk of future cardiac events. Prolongation of OT may be explained by the antiplatelet effects of Aspirin and Clopidogrel, as both these drugs prolong time to thrombus formation and hence increase OT. Further large studies are required to study factors which can reduce thrombogenic potential, and improve endogenous thrombolytic activity, which can be monitored using the GTT to improve cardiovascular outcomes.
APA, Harvard, Vancouver, ISO, and other styles
10

Wootton, David MacMullen. "Mechanistic modeling of occlusive arterial thrombosis." Diss., Georgia Institute of Technology, 1998. http://hdl.handle.net/1853/17351.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Thrombosis"

1

Chazov, E. I., and V. N. Smirnov, eds. Thrombosis and Thrombolysis. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

I, Chazov E., and Smirnov V. N. 1937-, eds. Thrombosis and thrombolysis. New York: Consultants Bureau, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

F, Pérez-Gómez, Prentice C. R. M, and Meyer Jürgen MD, eds. Coronary thrombosis: Intracardiac thrombosis. New York, NY: Raven Health Care Communications, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Becker, Richard C., ed. Textbook of Coronary Thrombosis and Thrombolysis. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/b102433.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

C, Becker Richard, ed. Textbook of coronary thrombosis and thrombolysis. Boston: Kluwer Academic Publishers, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Association, Canadian Medical, ed. Thrombosis. Toronto: Key Porter Books, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1927-, Sasahara Arthur A., and Loscalzo Joseph, eds. New therapeutic agents in thrombosis and thrombolysis. 2nd ed. New York: M. Dekker, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1927-, Sasahara Arthur A., and Loscalzo Joseph, eds. New therapeutic agents in thrombosis and thrombolysis. New York: M. Dekker, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

E, Freedman Jane, and Loscalzo Joseph, eds. New therapeutic agents in thrombosis and thrombolysis. 3rd ed. New York: Informa Healthcare USA, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

1931-, Kwaan Hau C., and Samama Meyer M, eds. Clinical thrombosis. Boca Raton, Fla: CRC Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Thrombosis"

1

Belitser, V. A., and T. V. Varetskaya. "Molecular Mechanisms of Fibrin Polymerization and Anticoagulant Action of Fibrinogen and Fibrin Degradation Products." In Thrombosis and Thrombolysis, 1–32. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gavrilov, O. K., and A. O. Gavrilov. "Apheresis Techniques (Gravitation Surgery) in the Regulation of the Hypercoagulable (Blood Aggregate) State." In Thrombosis and Thrombolysis, 237–54. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fedorova, Z. D., G. V. Samsonov, S. V. Kol’tsova, and N. A. Bynyaeva. "Pharmacodynamic Characteristics of Urokinin." In Thrombosis and Thrombolysis, 255–82. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Khvatov, V. B. "Plasmakinase: A New Thrombolytic Preparation from Postmortem Plasma." In Thrombosis and Thrombolysis, 283–310. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lakin, K. M., and V. A. Makarov. "Inhibitors of Platelet Aggregation." In Thrombosis and Thrombolysis, 311–63. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mazurov, A. V., V. L. Leytin, V. S. Repin, V. N. Smirnov, and W. Forster. "Platelet Spreading and the Formation of Thrombi-Like Aggregates on a Collagen Substrate. Effect of Soluble Inducers of Platelet Activity Under Different Hydrodynamic Conditions." In Thrombosis and Thrombolysis, 365–86. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Leytin, V. L., F. Misselwitz, A. G. Yumashkina, M. F. Bondarenko, E. V. Lyubimova, Yu A. Sharova, V. S. Repin, and V. N. Smirnov. "Impaired Platelet Adhesion to Collagen-Coated Surface in Patients with Bleeding Duodenal Ulcer (Direct Measurement of Platelet Adhesion in a Coulter-Type Cell Counter Following Elution of Adherent Platelets)." In Thrombosis and Thrombolysis, 387–99. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kubatiev, A. A., S. V. Andreev, and Ya D. Mamedov. "Biological Properties and Thrombolytic Activity of Proteinase from Aspergillus terricola." In Thrombosis and Thrombolysis, 401–26. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kudrjashov, B. A., and L. A. Lyapina. "Nonenzymatic Fibrinolysis and Its Role in the Organism." In Thrombosis and Thrombolysis, 33–63. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Andreenko, G. V. "Mechanisms of Enzymatic Fibrinolysis." In Thrombosis and Thrombolysis, 65–92. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1659-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Thrombosis"

1

Tomaru, Takanobu, Yasumi Uchida, Fumitaka Nakamura, Atsuko Miwa, Koichiro Yamada, and Tsuneaki Sugimoto. "Transluminal angiomicroscopy of arterial thrombosis and thrombolysis." In OE/LASE '92, edited by George S. Abela. SPIE, 1992. http://dx.doi.org/10.1117/12.137310.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Manco-Johnson, M. J., T. C. Abshire, and L. J. Jacobson. "FREQUENCY AND IMPLICATIONS OF SEVERE NEONATAL PROTEIN C DEFICIENCY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643609.

Full text
Abstract:
The newborn infant has a physiologically low level of protein C which rises very slowly in postnatal life. The frequency and significance of severe neonatal protein C deficiency has not been reported. In this study, protein C levels were measured in 110 newborn infants at the time of birth using functional (amidolytic, Cact) and immunologic (Laurell rocket, Cag) assays. The protein C levels were compared with a marker of thrombin activation (D-dimer fragment of fibrin, +D-D) and infants were subsequently followed for signs and symptoms of thrombosis. Results are summarized below (protein C levels are expressed as U/ml).Thirteen infants had protein C levels compatible with the homozygous deficiency state. Extremely low levels of protein C (<0.20 U/ml) were not found in well term infants and were rarely noted in stable preterm infants. D-D were infrequently present and no thrombosis occurred. Near term infants born with fetal distress frequently showed +D-D but rarely demonstrated extremely low levels of protein C. None of these infants required indwelling arterial catheters and no thromboses occurred. Preterm infants with severe respiratory distress showed lower protein C levels at birth (p <0.01). Although 71% had +D-D, thromboses in these infants were all related to invasive catheterizations. In contrast, the study population of twins demonstrated a high frequency of severe protein C deficiency with negative D-D and frequent thromboses, three of which occurred in the absence of instrumentation. In summary, severe protein C deficiency and thrombin activation are common in sick preterm infants with the risk of thrombosis increased by intravascular catheterization. In contrast, twins with severe protein C deficiency may manifest a thrombotic risk which is independent of thrombin activation or catheterization.
APA, Harvard, Vancouver, ISO, and other styles
3

Muzangwa, L. G., K. Lien, V. Rana, M. Groth, and A. Iftikhar. "Catheter-Directed Thrombolysis: Treatment of Acute Portal Vein Thrombosis." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2937.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hach-Wunderle, V., R. Walter-Fincke, H. K. Beck, and I. Scharrer. "FAMILY STUDIES OF PATIENTS WITH RECURRENT VENOUS THROMBOSES AND INHERITED DISORDERS OF BLOOD COAGULATION OR FIBRINOLYSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643045.

Full text
Abstract:
Several defects of the coagulation and/or fibrinolytic system have been found to be associated with venous thromboembolism. In young patients with recurrent thromboses or a positive family history, an inherited disorder should be excluded535 young patients with venous thromboses, phlebitis and/or pulmonary embolism were investigated from 1980 until 1986. The first thrombotic event had occurred at an age of less than 45 years.An inborn disorder of the blood coagulation or fibrinolytic system was found in 18 families. Most of them (n=13/18) had a positive family history. In all families either thromboses had occurred in at least one member (n=12/18) and/or the defect could be detected in one of them (n=12/18)Most often we found a deficiency of antithfombin III (n=6). A deficiency of protein C (type I) was detected in 3 and a deficiency of protein S in 5 families. In one patient a combined deficiency of anti thrombin III, protein C and protein S was found. Extensive family studies revealed a deficiency of antithrombin III in the grandmother of the patient, who suffered from arterial thrombosis. A deficiency of plasminogen and an abnormal plasminogen molecule were detected in 2 other families. Defective release of t-PA could be demonstrated in 3 members of one investigated family up to nowSeme family members with either defects of protein C, protein S or plasminogen as well as a defective release of t-PA lack thrombotic events. Furthermore thromboses of mesenteric veins occurred in 2 of 6 patients with anti thrombin III deficiency and in 1 of 5 patients with protein S deficiency. Superficial vein thromboses were mainly found in patients with protein C- or protein S-deficiency
APA, Harvard, Vancouver, ISO, and other styles
5

Fujimori, T., T. Saeki, K. Harada, M. Sato, and N. Ohshima. "ANTI-THROMBOTIC EFFECTS OF E-5510 IN EXPERIMENTAL THROMBOSIS MODELS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643429.

Full text
Abstract:
A new agent developed in our laboratory, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid (E-5510), suppressed various human platelet functions in vitro. The compound also showed quite potent ex vivo anti-platelet effects in many experimentalanimals. It is well known that anti-platelet effects are not always parallel to anti-thrombotic effects. Thus, in order to predict the efficacy of E-5510 in thrombotic disorders, the anti-thrombotic effects were examined in 3 different animal models of thrombosis.(1) Anti-thrombotic effect in an extracorporeal shunt model Two hrs after oral administration of the drug to guinea pigs,an extracorporeal shunt between the right carotid artery and the left jugular vein was performed. The thrombus formation on a silk thread inserted in the shunt tube was quantitated by measuring the time from the onset of circulation to the stenosis of blood flow. E-5510 dose-dependently inhibited thrombus formation, the minimum effective dose being 0.03 mg/kg.(2) Effect on microthrombus formation in mesenteric arteriole In order to evaluate the effect on intravascular platelet thrombus formation, thrombosis was induced in vivo in mesenteric arteriole in guinea pigs with filtered light from a mercury lamp and an intravenous fluorescent dye in an intravital microscope system (M. Sato and N. Ohshima, Thromb. Res.,35, 319, 1984). The thrombus formation was quantitated by measuring the time taken for circulating platelets to begin to adhere to vessel wall and the time taken for blood flow to stop completely due to fully developed thrombus. Both the time required for platelet adhesion to vessel wall and for platelet thrombus formation were significantly prolonged after oral administration of E-5510.(3) Effect on pulmonary thromboembolism Acute pulmonary thromboembolism was induced in mice by a bolus intravenous injection of arachidonic acid, and mortality was determined 3 min later. E-5510 dose-dependently reduced pulmonary thromboembolic mortality, and its ED50 was 0.11 mg/kg. The results described above indicate thatE-5510 may have beneficial effects in clinical treatments of thrombotic disease.
APA, Harvard, Vancouver, ISO, and other styles
6

Marín Barrera, Lucía, Luis Jara-Palomares, Álvaro Giráldez-Gallego, Teresa Elías-Hernández, María Isabel Asensio-Cruz, Aurora Solier-López, Lionel Suárez-Valdivia, and Remedios Otero-Candelera. "Unusual site thrombosis: splanchnic vein thrombosis, management in noncirrothic." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2441.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Finke, U., J. Schneider, E. Friderichs, L. Flohé, and H. Giertz. "MYOCARDIAL SALVAGE BY COMBINED TREATMENT WITH RECOMBINANT SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND RECOMBINANT HUMAN SUPEROXIDE DISMUTASE IN A CANINE CORONARY THROMBOSIS MODEL*." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643570.

Full text
Abstract:
Recanalization of thrombotic coronary occlusion with fibrinolytic treatment is a promising approach to salvage jeopardized ischemic myocardium. However, the success of thrombolytic treatment of myocardial infarction may be curtailed by the risk inherent to reperfusion. Cell damage upon reoxygenation after an ischemic period is tentatively attributed to the formation of oxygen-derived free radicals. Improved myocardial salvage is therefore expected from coadministration of a free radical scavenger and fibrinolytic treatment. We tested this hypothesis in a canine model of left anterior circumflex coronary artery (LCX) thrombosis. Thrombolysis was achieved with the fibrin- selective single-chain urokinase-type plasminogen activator of recombinant origin (r-scu-PA). As enzymatic scavenger of oxygen radicals recombinant human superoxide dismu-tase (r-HSOD) was used. The three experimental groups were: group I (n=4) did not receive any treatment after LCX thrombosis; in group II (n=9) at 100 min after LCX thrombosis r-scu-PA (20 μg/kg/min i.v. for 30 min) was infused; dogs in group III (n=8) received concomitant treatment with r-scu-PA and r-HSOD (10 mg/kg i.v. for 60 min). Infarct size as percent of the risk zone was 38.2 ± 4.1 in group I, 25.3 ± 3.7 in group II (p ≤ 0.05 vs group I) and 14.9 ± 3.2 in group III (p ≤ 0.05 vs group II). Incidence of reperfusion arrhythmias and increase in plasma CK were significantly diminished by r-HSOD when compared to dogs receiving r-scu-PA only. There were no significant differences in hemodynamic parameters between the groups. In conclusion, in terms of infarct size reduction, suppression of reperfusion arrhythmias and attenuation of intracellular enzyme release the combined treatment with r-scu-PA and r-HSOD yielded a significant higher myocardial salvage versus thrombolytic treatment alone in a canine LCX thrombosis model.* This work is part of the doctoral dissertation of Miss U. Fincke
APA, Harvard, Vancouver, ISO, and other styles
8

Singh, Bhavneet, Gurkirat Singh, and Arvind Lee. "Acute SMA Thrombosis." In PAIRS 2023 Annual Congress. Thieme Medical and Scientific Publishers Pvt. Ltd., 2023. http://dx.doi.org/10.1055/s-0043-1763384.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hussein, Emad A. "Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis: Predictors of Outcome." In PAIRS Annual Meeting. Thieme Medical and Scientific Publishers Pvt. Ltd., 2020. http://dx.doi.org/10.1055/s-0041-1729020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Schwartz, R., E. Kavanagh, K. Bauer, R. Rosenberg, J. Ballard, J. Latino, V. Strother, M. Mosesson, W. Haire, and M. DeLeo. "ANTITHROMBIN III CONCENTRATE (AT-III) FOR PROPHYLAXIS ANDTREATMENT OF CONGENITAL AND ACQUIREDAT-III DEFCIENCY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643678.

Full text
Abstract:
An investigation has been undertakenin 13 patient studies to determine the efficacy of AT-III in prevention and treatment of thrombosis in patients with congenital (cong.) and acquired (acq.) AT-III deficiency. The mean in vivo incremental recovery of 17 infusions of AT-III in 7 patientswith cong. AT-III deficiency (2 kinetic studies, 5 prophylaxis) was 1.4%/U/kg (functional assay) administered. The mean in vivo recovery of 38 infusions in 4 non-bleeding patients(3 cong., 1 acq.) treated for thrombosis or pulmonary embolism (P.E.) with heparin was 1.33%/U/kg which was not significantly different. The half-life determined in an earlier study exceeded 2.5 days. All patients treated prophylactically or therapeutically received a loading dose to increase plasma AT-III to 120%, and then received maintenance doses, generally every 24 hours, to maintain plasma AT-III levels in the general range 80-120%. AT-III levels were monitored every 12 hours initially and doses and intervals modified accordingly. None of 5 patients with cong. deficiency treated prophylactically for high risk situations (surgery, delivery, catheterization) developed a thrombotic complication. Six patients (3 cong., 2 acq., 1 probably acq.) were treated for thrombosis/P.E., two of whom were pregnant. Heparin resistance was reversed in two, both pregnant. One patient with superior mesenteric-portal vein thrombosis (cong. deficiency) and another with superior mesenteric artery-aortic occlusion (acq. deficiency) survived without further progression of thrombosis. DIC resolved in one patient treated with AT-III and benefit was observed in a 2nd patient as well. AT-III was well tolerated, with but a single mild reaction in 176 infusions. We conclude AT-III may be beneficialas prophylaxis in patients with cong.AT-III deficiency during high thrombotic risk situations, as well as anadjunct to heparin in treatment for thrombotic complications in congenital and acquired AT-III deficiency.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Thrombosis"

1

Liu, Cheng. Synergism of Selective Tumor Vascular Thrombosis and Protease Activated Prodrug. Fort Belvoir, VA: Defense Technical Information Center, May 2008. http://dx.doi.org/10.21236/ada494207.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shi, Guoxin, and Wen Zhao. Risk factors for deep venous thrombosis in patients with stroke: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Akbari, Ardalan. Luc’s Abscess: First Reported Case with Coexisting Intracranial Abscess and/or Venous Sinus Thrombosis. Science Repository OÜ, August 2018. http://dx.doi.org/10.31487/j.scr.2018.03.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

LI, Weihui LI, Feng Xu, Weijing Fan, Guobin Liu, Lei Xu, Xvhong Wang, Huimin Lu, and Yuanxiang LI. Xueshuantong injection in treating Deep Venous Thrombosis: a systematic review and experimental sequential analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2020. http://dx.doi.org/10.37766/inplasy2020.12.0117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Xiong, Yuchen, Weiwei Wu, and Shanzi Yu. Different spine tumor pathology and risk of venous thrombosis : systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2023. http://dx.doi.org/10.37766/inplasy2023.3.0121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jia, Xuanjing. Meta-analysis of the preventive effect of neuromuscular electrical stimulation on postoperative deep vein thrombosis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2024. http://dx.doi.org/10.37766/inplasy2024.9.0072.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hatzfeld, Jennifer, Maria Kohler, and Susan Dukes. FDG20100017H Incidence of Venous Thomboembolism 9VTE) and Effect of Thrombosis Prophylaxis Guidelines in Patients Transported Aeromedically. Fort Belvoir, VA: Defense Technical Information Center, May 2014. http://dx.doi.org/10.21236/ada608673.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cheng, Fangqun, Biyun Ye, Ying Tang, Zhuo Xiao, Dan Liu, Ke Wang, Peiyu Cheng, and Jingping Zhang. Risk factors for deep vein thrombosis in patients with cerebral hemorrhage: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0068.

Full text
Abstract:
Review question / Objective: To identify the risk factors of deep venous thrombosis in patients with cerebral hemorrhage. Eligibility criteria: Inclusion criteria: ①Comply with the “Guidelines for diagnosis of cerebral hemorrhage in China”[7] or “Guidelines for the management of spontaneous intracerebral hemorrhage in the United States”[37], or be diagnosed as ICH in combination with brain CT, MRI, and cerebral angiography; ②Age ≥18 years old; ③Ultrasonography or color polygraph Pler ultrasonography confirmed DVT; ④ The study type was cohort study or case-control study; ⑤ Newcastle-Ottawa Scale (NOS) [8] score ≥ 6 points; ⑥ The language was limited to Chinese and English. Exclusion criteria: ① Repeated publications; ② Studies without full text, incomplete information, or data extraction impossible.
APA, Harvard, Vancouver, ISO, and other styles
9

Gong, Wei, Yongqi Li, Yu Tian, Jing Zhang, and Lei Li. Effects of cardiovascular disease and traditional cardiovascular risk factors on deep vein thrombosis in stroke patients: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wang, Liangshan, Yan Wang, Wenjing Qin, Wei Chen, Zhongtao Du, Hong Wang, Yijiang Li, Xiaotong Hou, and Lingxia Zeng. The incidence of bleeding and thrombosis among patients receiving extracorporeal membrane oxygenation (ECMO): a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2023. http://dx.doi.org/10.37766/inplasy2023.5.0039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Thrombosis' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography